A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

NCT01609543 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: erlotinib [Tarceva]

Sponsor

Hoffmann-La Roche